Idera Pharmaceuticals Inc.’s (Nasdaq: IDRA) stock dropped more than 5 percent Monday, following the company’s announcement that it would delay the launch of a clinical trial on its drug candidate for hepatitis C, due to toxicology study results on rodents that showed instances of atypical proliferation of a type of white blood cells, called lymphocytes. High levels of lymphocytes are generally associated with viral infections.
The company announced its decision on Friday, when the markets were closed.
SOURCE